PCSK9, His, Cynomolgus

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.

Price	$340.00
Cat. No.	Z04891-100
Size	100 μg 500 μg Buy in bulk
Quantity
Est. Delivery


Ask us a question

Product Introduction Background Bottom Notes

Product Introduction

Species

Cynomolgus

Protein Construction

PCSK9 (Glu151-Gln811) Accession # A0A2K5TZC4	His
N-term	C-term

Purity

> 95% as determined by BisTris PAGE

Endotoxin Level

Less than 1EU per μg by the LAL method.

Biological Activity

Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.

Expression System

HEK293

Theoretical Molecular Weight

the pro-form (59 kDa) and mature form (14 kDa)

Apparent Molecular Weight

Due to glycosylation, the protein migrates to 65-70 kDa (pro-form) and 15-20 kDa (mature form) based on Bis-Tris PAGE result.

Formulation

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).

Reconstitution

Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

Storage & Stability

Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Back

Immobilized PCSK9, His, Cynomolgus, His Tag at 5 μg /ml(100 μl /well) on the plate. Dose response curve for Anti-PCSK9 Antibody, hFc Tag with the EC50 of 88.7ng/ml determined by ELISA. »

The purity of PCSK9, His, Cynomolgus is greater than 95% as determined by SEC-HPLC. »

PCSK9, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

Cynomolgus LDLR, His Tag immobilized on CM5 Chip can bind PCSK9, His, Cynomolgus, His Tag with an affinity constant of 0.27 nM as determined in SPR assay (Biacore T200). »

Background

Target Background	Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.
Synonyms	PCSK9

Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.